Navigation Links
Corium International Adds Dr. Bhaskar Chaudhuri and David Greenwood to Board of Directors
Date:2/3/2011

MENLO PARK, Calif., Feb. 3, 2011 /PRNewswire/ -- Corium International, Inc., a privately-held advanced transdermal drug delivery company, today announced the appointment of Dr. Bhaskar Chaudhuri and David L. Greenwood to the Board of Directors.  Dr. Chaudhuri most recently served as President of Valeant Pharmaceuticals International and previously was President and Chief Executive Officer of Dow Pharmaceutical Services, Inc.  Mr. Greenwood is Executive Vice President and Chief Financial Officer of Geron Corporation.  

"We are excited and honored to welcome two executives of Bhaskar and David's caliber to Corium's Board of Directors," said Peter Staple, Corium's President and Chief Executive Officer.  "They bring a breadth of experience and accomplishments that will be invaluable as Corium advances through its next stages of growth."With well over 20 years of industry management experience, Dr. Chaudhuri brings extensive product development and commercialization knowledge to Corium.  Before joining Dow, he served as Vice President of R&D at Penederm, Inc., as General Manager of the Dermatology Division of Mylan Laboratories, and as Executive Vice President of Scientific Affairs at Bertek Pharmaceuticals, a subsidiary of Mylan, where he was responsible for research and development activities as well as certain of the company's manufacturing operations.  As Chief Executive Officer of Dow, Dr. Chaudhuri led the company through a transition from a contract development focus to developing an attractive internal product pipeline and the company's eventual merger with Valeant.  Dr. Chaudhuri holds a Doctorate in Physical Pharmacy, a Master's of Science in Industrial Pharmacy and a Bachelor's of Science in Pharmacy.

Mr. Greenwood brings substantial expertise in financing pharmaceutical and biotechnology companies. Before joining Geron, he held various positions in the investment banking field for over 15 years, including the international investment bank, J.P. Morgan & Co. Incorporated.  He joined Geron in 1995 as the company's Chief Financial Officer, Treasurer and Secretary and has also served as the company's Vice President of Corporate Development.  Mr. Greenwood is a director of two of the company's subsidiaries, Geron Bio-Med Limited and TA Therapeutic Ltd. as well as a director of ViaGen, Inc., an Arizona corporation, and Clone International, an Australian company.  Mr. Greenwood serves on the Board of Regents of Pacific Lutheran University from which he holds a Bachelor of Arts.  He also has an M.B.A. from Harvard Business School.

Dr. Chaudhuri and Mr. Greenwood join current Corium board members Ron Eastman, Chairman of the Board of Corium and Managing Director at Essex Woodlands Health Ventures, Dr. Phyllis Gardner, Partner at Essex Woodlands and Professor of Medicine at Stanford University, John Kozarich, Chairman and President, ActivX Biosciences, Inc., Robert Thomas, former CEO of FoxHollow Technologies, Daniel G. Welch, CEO and President of InterMune, Peter D. Staple, CEO and President of Corium and Gary W. Cleary, co-founder of Corium.  The Company is currently developing and manufacturing a pipeline of advanced transdermal products employing its proprietary MicroCor® microneedle technology and Corplex™ polymer adhesive technology.  Essex Woodlands Health Ventures has been the lead investor in Corium since 2007.

Corium is headquartered in Menlo Park, CA, with manufacturing facilities in Grand Rapids, MI.

About Corium International, Inc.

Corium International, Inc. develops and manufactures products based on its advanced transdermal drug delivery technologies.  The company has developed and clinically validated two highly differentiated state of the art transdermal technologies: MicroCor® is designed for needle-free delivery of large molecules such as proteins and peptides, and Corplex™ enables the "steady-state" delivery of small molecules. Corium develops and manufactures both self-funded proprietary products and products for its partners, which include specialty pharma, biotech and large, established pharmaceutical companies.  Please visit www.coriumgroup.com.Contact

Corium International, Inc.Christina DickersonVice President, Corporate Development650.298.8257christina@coriumtech.com
'/>"/>

SOURCE Corium International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Encorium Group Signs $6.2 Million of New Contracts Mainly for Vaccines Clinical Trials
2. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
3. Encorium Group Provides Update to LOI with Respect to the Sale of its U.S. Business
4. Encorium Re-Appoints Dr. Kai Lindevall as Chief Executive Officer and Appoints Current Director, Shahab Fatheazam, Chairman of the Board
5. Encorium Group, Inc. Appoints Sari Laitinen to Board of Directors
6. Encorium Group, Inc. Acquires Progenitor International Research, a Vaccine Focused Emerging Market CRO
7. Encorium Reports Second Quarter 2010 Financial Results
8. Encorium Group, Inc. Announces Terms of Proposed Rights Offering
9. Encorium Group, Inc. Provides Update on Its Previously Announced Rights Offering
10. Encorium Group, Inc. Extends Expiration of Its Pending Rights Offering
11. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... , Aug. 15, 2017 Diplomat Pharmacy, Inc. ... Michigan residents. Naloxone ... Flint retail pharmacy, G-3320 Beecher Road. ... the Food and Drug Administration, is intended to block ... slowed breathing, and loss of consciousness. The medication is ...
(Date:8/14/2017)... TIKVAH, Israel , Aug. 15, 2017 ... developer of adult stem cell technologies for neurodegenerative diseases, ... 30, 2017. "We ... pivotal Phase 3 trial to investigate NurOwn ® ... Chief Executive Officer of BrainStorm. "We have agreements with ...
(Date:8/8/2017)... --   Second-quarter 2017 revenues ... per share from continuing operations ... percent to $110 million ... $161 million Second-quarter 2017 ... increased 8 percent to $0.93 ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... ... Elemental LED, a leading U.S. based engineering and technology company that ... honored with Architectural SSL Product Innovation Awards (PIA) for the most innovative ... LED, provides a wide variety of superior quality linear, task, and accent LED lighting ...
(Date:8/17/2017)... ... August 17, 2017 , ... In its just released 2018 ... and Harry Nelson. This is the third consecutive year that Hardiman and Mills have ... were both recognized for expertise in Health Care Law while Mills was recognized in ...
(Date:8/17/2017)... ... August 17, 2017 , ... With the introduction of new devices, ... number of changes to the smartwatch market. As of June 2017, nearly nine percent ... the six months prior. Additionally, according to latest WEAR Report Industry Overview and Forecast ...
(Date:8/17/2017)... ... 17, 2017 , ... Momkus McCluskey Roberts LLC recently announced it ... member of the firm’s Commercial Litigation and Employment Law groups. , Ms. Parks joined ... in matters of employment litigation, commercial litigation and business disputes. Her experience includes all ...
(Date:8/17/2017)... , ... August 17, 2017 , ... ... Business Development Group, a Florida-based oncology business advisor to oncology practices, announced today ... the dollar amount of attributable savings from resolving critical clinical issues that would ...
Breaking Medicine News(10 mins):